Incremental gains and a long road ahead in MDS

ONCOLOGY

Volumn 22, Issue 12, 2008, Pages

  Steensma, David P ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IRON CHELATION; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEMATINICS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 57449107379     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Steensma DP, Tefferi A: Risk-based management of myelodysplastic syndrome. Oncology (Williston Park) 21:43-62 (incl discussion), 2007.
2. Fenaux P, Mufti GJ, Santini V, et al: Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study (abstract 817). Blood 110:250a, 2007.
3. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
4. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007.
5. van de Loosdrecht AA, Westers TM, Westra AH, et al: Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111: 1067-1077, 2008.
6. Loken MR, van de Loosdrecht A, Ogata K, et al: Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 32:5-17, 2008.
7. Holtan SG, Santana-Davila R, Dewald GW, et al: Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era. Am J Hematol 83:708-713, 2008.
8. Wimazal F, Sperr WR, Kundi M, et al: Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 25:287-294, 2001.
9. Marisavljevic D, Cemerikic V, Rolovic Z, et al: Hypocellular myelodysplastic syndromes: Clinical and biological significance. Med Oncol 22-169-175, 2005.
10. Yue G, Hao S, Fadare O, et al: Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res 32:553-558, 2008.
11. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in mds and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110:4385-4395, 2007.
12. Mohamedali A, Gaken J, Twine NA, et al: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365-3373, 2007.
13. Gondek LP, Haddad AS, O'Keefe CL, et al: Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Experimental hematology 35:1728-1738, 2007.
14. Miller KB, Kim HT, Greenberg P, et al: Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): Results of the ECOG-CLSG trial (E1996) (abstract 70). Blood 104:24a, 2004.
15. Chacko J, Pennell DJ, Tanner MA, et al: Myocardial iron loading by magnetic resonance imaging t2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138:587-593, 2007.
16. Konen E, Ghoti H, Goitein O, et al: No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 82:1013-1016, 2007.
17. Stone R: Elevated serum ferritin in patients with a myelodysplastic syndrome: How much of a problem? Am J Hematol 83:609-610, 2008.
18. Chee CE, Steensma DP, Wu W, et al: Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83:611-613, 2008.
19. Tefferi A: Iron chelation therapy for myelodysplastic syndrome: If and when. Mayo Clin Proc 81:197-198, 2006.
20. Armand P, Yim HT, Cutler CS, et al: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588, 2007.